Subscribe
shutterstock_1776573179_rafapress
rafapress / Shutterstock.com
2 September 2021GenericsAlex Baldwin

Endo International can’t stop Vasostrict generic

The US District Court for the District of Delaware has ruled that one of Endo International’s pharma units cannot stop a generic of its blood pressure drug Vasostrict (vasopressin injection) from being made.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Endo pays $2.3m to settle states antitrust claims
22 July 2019   Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
Americas
Endo resolves FTC allegations over Lidoderm and Opana ER
24 January 2017   Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission by abandoning anti-competitive pay-for-delay agreements.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Endo pays $2.3m to settle states antitrust claims
22 July 2019   Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
Americas
Endo resolves FTC allegations over Lidoderm and Opana ER
24 January 2017   Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission by abandoning anti-competitive pay-for-delay agreements.

More on this story

Americas
Endo pays $2.3m to settle states antitrust claims
22 July 2019   Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
Americas
Endo resolves FTC allegations over Lidoderm and Opana ER
24 January 2017   Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission by abandoning anti-competitive pay-for-delay agreements.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility